2020 CINP World Congress

25-28 June 2020 Taipei, Taiwan

First Announcement & Call for Abstracts

cinp2020.org | cinp2020@cinp.org
On behalf of the Executive Committee of the International College of Neuropsychopharmacology (CINP), it is my pleasure to invite you to the 32nd CINP World Congress of Neuropharmacology in Taipei, Taiwan in June 2020. This upcoming World Congress welcomes delegates from all over the globe to the beautiful city of Taipei to carry on the momentum of the previous World Congresses in Seoul and Vienna. Building on our previous efforts, we will expand our core mission of linking the advances in brain sciences to the alleviation of the distress and disabilities associated with neuropsychiatric disorders. With advances in neuroscience, this is an exciting time for the understanding of psychiatric pathophysiology and the 32nd World Congress will feature the most up-to-date research, diverse topics of interest, and educational sessions with leading experts.

We hope that you will be able to join us to advance the research and education of psychopharmacology.

Professor Siegfried Kasper
President of CINP (2018 – 2020)
Taipei International Convention Center

Important Dates

15 November 2019
Registrations open

15 November 2019
Abstract submissions open

30 January 2020
Abstract submissions close

Visit www.cinp2020.org to submit your abstract and register!
The International College of Neuropsychopharmacology (CINP) is a truly worldwide organization established over 50 years ago in Zurich, Switzerland. CINP hold meetings all over the world with the aim to promote research and education on a worldwide basis. With the change to go annual with the CINP World Congress, the college will also focus more on smaller seminars and workshops in between.

The Executive Committee and Councilors of CINP are nominated by the membership and serve as an officer of the College for a minimum of 4 years. These individuals cover a wide range of disciplines within the field, from psychiatrists, psychopharmacologists, basic and clinical researchers to clinical psychologists. CINP also relies on its many subcommittees who undertake a variety of activities for the College.

Membership of the College is available to any individual to apply for and we offer members the opportunity to become part of this knowledgeable group of scientists who work at an international level. The membership application is reviewed by a dedicated committee on a regular basis and applications can be made online. As a member of CINP you may have the opportunity to be invited to one of the smaller meetings or invited to participate in the running of the College by sitting on a subcommittee.

Oxford University Press has a rich history dating back to 1478; today OUP has 6,000 employees in offices in 50 countries and is the largest university press in the world. OUP has an incredibly diverse publishing program; publishing in more than 40 languages and in a variety of formats—print and digital, for all audiences—from pre-school to secondary level schoolchildren; students to academics; general readers to researchers and clinicians; individuals to institutions. As a department of the University of Oxford, our worldwide publishing furthers the University’s objectives of excellence in scholarship, research, and education.

For more information about the College visit www.cinp.org
CINP 2020 Committees

Executive Committee
CINP President
Siegfried Kasper, Austria
CINP Past President
John H. Krystal, USA
CINP President Elect
Pierre Blier, Canada
CINP Vice President
Shih-Ku Lin, Taiwan
CINP Vice President
Joseph Zohar, Israel
CINP Secretary
Elias Eriksson, Sweden
CINP Treasurer
Kazutaka Ikeda, Japan

Councillors
Helena Calil, Brazil
Ryota Hashimoto, Japan
Katharina Domschke, Germany
Jun Soo Kwon, Republic of Korea
Atsumi Nitta, Japan
Peter Falkai, Germany
Maurizio Fava, USA
Carol Tamminga, USA
Allan Young, United Kingdom
Gabriella Gobbi, Canada

International Scientific Programme Committee
Chair
Pierre Blier, Canada
Co-chair
Elias Eriksson, Sweden
Co-chair
Noriko Osumi, Japan

Chiou, Lih-Chu, Taiwan
Cryan, John, Ireland
Domschke, Katharina, Germany
Falkai, Peter, Germany
Fountoulakis, Kostas, Greece
Frazer, Alan, USA
Gobbi, Gabriella, Canada
Huang, Ming-Chyi, Taiwan
Hiroi, Noboru, USA
Ikeda, Kazutaka, Japan
Kasper, Siegfried, Austria
Kwon, Jun Soo, Korea
Krystal, John, USA
Lanzenberger, Rupert, Austria
Lin, Shih-Ku, Taiwan
McGuire, Philip, UK
Morilak, David, USA
Shamay-Tsoory, Simone, Israel
Soldatos, Constantin, Greece
Tamminga, Carol, USA
Uchida, Hiroyuki, Japan
Yamawaki, Shigeto, Japan
Zohar, Joseph, Israel
Local Organizing Committee

Co-chair
Shih-Ku Lin, Taiwan

Co-chair
Yen-Kuang Yang, Taiwan

Co-chair
Po-See Chen, Taiwan

Bai, Ya-Mei, Taiwan
Chen, Cheng-Sheng, Taiwan
Chen, Chia-Hsiang, Taiwan
Chen, Chih-Cheng, Taiwan
Chen, Chih-Ken, Taiwan
Chiou, Lih-Chu, Taiwan
Chong, Mian-Yoon, Taiwan
Gau, Shur-Fen, Taiwan
Gean, Po-Wu, Taiwan
Huang, Ming-Chyi, Taiwan
Huang, San-Yuan, Taiwan
Huang, Tiao-Lai, Taiwan
Hwang, Tzung-Jeng, Taiwan
Ko, Chih-Hung, Taiwan
Lane, Hsien-Yuan, Taiwan
Lee, Chau-Shoun, Taiwan
Liu, Chia-Yih, Taiwan
Liu, Yu-Li, Taiwan
Shen, Winston W., Taiwan
Su, Kuan-Pin, Ta
Su, Tung-Ping, Taiwan

South Asia & South-East Asia Committee (SASEAC)

Co-chair
Yen-Kuang Yang, Taiwan

Co-chair
Po-See Chen, Taiwan

Andi Jayalangkara Tanra, Indonesia
Azimatul Karimah, Indonesia
Dang Duy Thanh, Vietnam
Kim Savuon, Cambodia
Kristian Liaury, Indonesia
Kua Ee Heok, Singapore
Ng Chong Guan, Malaysia
Samai Sirithongthaworm, Thailand
Tjhin Wiguna, Indonesia
Tu Trung Lam, Vietnam

AsCNP Committee

Chair
Kazutaka Ikeda, AsCNP President, Japan

Co-chair
Chay Hoon Tan, AsCNP President-Elect, Singapore

Co-chair
Andi J. Tanra, AsCNP Past President, Indonesia

Atsumi Nitta, Japan
Chan Hyung Kim, Korea
Sangyeol Lee, Korea
Shigeto Yamawaki, Japan
Shih-Ku Lin, Taiwan
Suresh Sundram, Australia
Tianmei Si, China
Young Chul Chung, Korea
The CINP Executive Committee welcomes the submission of abstracts for **poster presentations**.

A small number of the abstracts intended for posters will be selected to be presented as 15+3 min **oral presentations** in a symposium on the topic in question. Please indicate on the submission form if you want your abstract to be considered for an oral presentation.

If you are 35 years old or younger, please consider applying for the Rafaelsen Young Investigators Travel Award. Visit www.cinp2020.org for more details.

**Abstract submissions should preferably be structured as follows:**
- Background
- Aims & Objectives
- Methods
- Results
- Discussion & Conclusion
- References – use Harvard style, where each reference is numbered in order of use

**Submission Guidelines**
- Abstracts must be in English
- The abstract must not exceed 500 words
- A table or figure will count as 150 words
- The total word count does not include the title, authors' details or references
- The name of the presenting author should appear first in the list of authors
- CINP recommends using the NbN nomenclature for psychotropics (nbn2r.com)

**Important Deadlines**
- **Abstract submission**
  Deadline: 30 January 2020
- **Notification of Acceptance/Rejection:**
  2 March 2020
- **Change of Title/Authorship:**
  Deadline: 16 March 2020
- **Presenting Author Registration**
  Deadline: 16 March 2020

Submit your abstract now! www.cinp2020.org/abstract-submissions
# Programme at a Glance

## Thursday, 25 June 2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 17:30</td>
<td>Room 201 A</td>
<td>Pre-Congress workshop on managing treatment resistant depression in 2020 Diane McIntosh, Canada</td>
</tr>
<tr>
<td></td>
<td>Room 201 B</td>
<td>Pre-Congress workshop on on challenging cases of OCD: from diagnosis to treatment Joseph Zohar, Israel</td>
</tr>
<tr>
<td></td>
<td>Room 201 C</td>
<td>Pre-Congress workshop on rational and irrational polypharmacy Pierre Blier, Canada</td>
</tr>
<tr>
<td></td>
<td>Room 201 D</td>
<td>Early career researchers’ workshop: Clinical research in progress on addictive medicine</td>
</tr>
<tr>
<td></td>
<td>Room 201 E</td>
<td>Pre-Congress workshop on research in Asian Psychotropic Drug Prescription (REAP): Past, present and future</td>
</tr>
<tr>
<td>18:30 - 19:45</td>
<td></td>
<td>Opening and Awards Ceremony</td>
</tr>
<tr>
<td>19:45 - 21:00</td>
<td></td>
<td>Welcome Reception</td>
</tr>
</tbody>
</table>

**LEGEND**
- Light Yellow: Plenary Lecture
- Light Blue: Symposium
- Light Pink: Debate
- Light Grey: Regional Symposium
- Light Green: Pre-Congress Workshop
- Light Green: Clinical Focus and Frontiers
- Light Green: The Selected One
- Light Pink: Session in Chinese
- Light Grey: Other

---

## Download the CINP Mobile App

**How to download**
- Scan one of these barcodes.
- Search ‘CINP’ in the Apple App or Google Play Store.

---

[Scan QR Code](http://bit.ly/2DzW4RL)

http://bit.ly/2DxmJi0  
[Scan QR Code](http://bit.ly/2DxmJi0)
**Friday, 26 June 2020**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45 - 09:30</td>
<td>Plenary Lecture: From genes to clinical phenotype in ADHD across the lifespan - Barbara Franke, Radboud University, The Netherlands</td>
<td>Plenary Hall Room 201 A+B+C</td>
</tr>
<tr>
<td>09:30 - 10:00</td>
<td>Networking Break</td>
<td></td>
</tr>
</tbody>
</table>
| 10:00 - 11:30 | Symposium 1: Gene-environment interaction in schizophrenia: Genetic load modulates the deleterious impact of stressors to lead to the emergence of psychosis  
Symposium 2: Treatment Resistant Depression (TRD)  
Symposium 3: Novel brain imaging strategies to assess pathophysiology and treatment effects in neuropsychiatric disorders  
Regional Symposium  
The selected ones (Oral Abstracts) (Theme A)  
The selected ones (Oral Abstracts) (Theme B)  
Next generation seizure therapy and neuromodulation (in Chinese) | Room 201 D+E+F Room 101 A+B Room 101 C+D Room 102 Room 105 |
| 11:30 - 13:00 | Lunch  
Satellite Symposia  
Plenary Educational Workshops (PEW)  
Meet with... John (Krystal): Psychosis*  
Meet with... Katharina (Domschke): Anxiety*  
*Pre-registration required; preference given to CINP members | Room 101 A+B Room 102 Room 105 |
| 13:00 - 14:30 | Symposium 4: Substance abuse and psychosis: New insights on old problems  
Symposium 5: Partial dopamine agonists: Wide spectrum medications for psychiatric disorders  
Symposium 6: Ethical Challenges of Genomic Research in Neuropsychiatric Disorders  
In the pipeline  
Behaviour addiction session  
Clinical focus and frontiers (OCD)  
Non-substance addictive disorders (behavioral addiction) (in Chinese) | Room 201 A+B+C Room 101 A+B Room 101 C+D Room 102 Room 105 |
| 14:45 - 16:15 | Symposium 7: The interplay of stress cascade and NMDAR dysfunction in the pathogenesis of mental disorders identifying novel antioxidants and NMDAR modulators for treatment and diagnosis  
Symposium 8: Altered Circadian Rhythms in Psychiatric Mood Disorders: New Treatment Strategies  
Symposium 9: Opioid Pharmacology Updates: toward precision pharmacotherapy  
Editors' Top Publications - session 1  
Debate Cannabinoids Gabriella Gobbi vs. David Nutt  
Clinical focus and frontiers (ADHD)  
Pharmacokinetic and pharmacogenetics (in Chinese) | Room 201 A+B+C Room 101 A+B Room 101 C+D Room 102 Room 105 |
| 16:15 - 16:45 | Networking Break                                                     |                           |
| 16:45 - 17:30 | Plenary Lecture: What is life: implications for brain health - Josef Penninger, Life Sciences Institute, UBC, Canada | Room 201 A+B+C Room 101 A+B Room 101 C+D Room 102 Room 105 |
| 18:00 - 19:30 | Top 10 posters - guided session                                       |                           |

**Legend**
- Plenary Lecture
- Symposium
- Debate
- Regional Symposium
- Pre-Congress Workshop
- Clinical Focus and Frontiers
- The Selected One
- Session in Chinese
- Other
### Programme at a Glance

**Saturday 27 June 2020**

<table>
<thead>
<tr>
<th>Time</th>
<th>Venue</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45</td>
<td>PLENARY HALL</td>
<td>Plenary Lecture: Big data analyses for neuropsychopharmacology</td>
</tr>
<tr>
<td>08:45</td>
<td>ROOM 201 A+ B+C</td>
<td>Tung-Ping Su, Cheng-Hsin General Hospital, Taiwan</td>
</tr>
<tr>
<td>09:30</td>
<td>ROOM 201 D+E+F</td>
<td>Networking Break</td>
</tr>
<tr>
<td>09:30</td>
<td>ROOM 101 A+B</td>
<td>Plenary Educational Workshops (PEW)</td>
</tr>
<tr>
<td>10:00</td>
<td>ROOM 101 C+D</td>
<td>Lunch</td>
</tr>
<tr>
<td>10:00</td>
<td>ROOM 102</td>
<td>Satellite Symposia</td>
</tr>
<tr>
<td>11:30</td>
<td>ROOM 105</td>
<td>Editors’ Top Publications - session 2</td>
</tr>
</tbody>
</table>

**Programme at a Glance**

- **08:45 - 09:30**
  - **PLENARY HALL**
    - **Room 201 A+ B+C**: Plenary Lecture: Big data analyses for neuropsychopharmacology by Tung-Ping Su, Cheng-Hsin General Hospital, Taiwan.
- **09:30 - 10:00**
  - **Room 201 D+E+F**: Networking Break.
  - **Room 101 A+B**: Plenary Educational Workshops (PEW).
  - **Room 101 C+D**: Lunch.
  - **Room 102**: Satellite Symposia.
  - **Room 105**: Editors’ Top Publications - session 2.

**LEGEND**

- Plenary Lecture
- Symposium
- Debate
- Regional Symposium
- Pre-Congress Workshop
- Clinical Focus and Frontiers
- The Selected One
- Session in Chinese
- Other
## Programme at a Glance

### Sunday 28 June 2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45 - 09:30</td>
<td>Plenary Lecture: Transgenerational epigenetics: A key to understand neurodevelopmental diseases - Noriko Osumi, Tohoku University, Japan</td>
</tr>
<tr>
<td>09:30 - 10:00</td>
<td>Networking Break</td>
</tr>
<tr>
<td>10:00 - 11:30</td>
<td>Symposium 19: Estrogen and psychiatric illnesses</td>
</tr>
<tr>
<td></td>
<td>Symposium 20: Epigenomic pathophysiology of Bipolar Disorder: Human tissue investigations of mechanisms, biomarkers, and single-cell pathology</td>
</tr>
<tr>
<td></td>
<td>Symposium 21: Stronger together? Using PET and MRI in neuropsychopharmacology</td>
</tr>
<tr>
<td></td>
<td>Regional Symposium</td>
</tr>
<tr>
<td></td>
<td>The selected ones (Oral Abstracts) (Theme E)</td>
</tr>
<tr>
<td></td>
<td>Clinical focus and frontiers (Insomnia)</td>
</tr>
<tr>
<td>11:30 - 13:00</td>
<td>Lunch</td>
</tr>
<tr>
<td></td>
<td>Satellite Symposia</td>
</tr>
<tr>
<td></td>
<td>Plenary Educational Workshops (PEW)</td>
</tr>
<tr>
<td></td>
<td>Meet with... Gabriella (Gobbi): Cannabis*</td>
</tr>
<tr>
<td></td>
<td>Meet with... Elias (Eriksson): Antidepressants*</td>
</tr>
<tr>
<td></td>
<td>*Pre-registration required; preference given to CINP members</td>
</tr>
<tr>
<td>13:00 - 14:30</td>
<td>Symposium 22: Transgender hormone therapy: effects on brain structure and function</td>
</tr>
<tr>
<td></td>
<td>Symposium 23: Mechanisms of stress response at the single cell resolution</td>
</tr>
<tr>
<td></td>
<td>Symposium 24: Novel Molecular and Cellular Mechanisms of Rapid-acting Antidepressant Ketamine and Its Enantiomers</td>
</tr>
<tr>
<td></td>
<td>Debate: Is long-term treatment with antipsychotics justified? Konstantinos Fountoulakis vs. Robin Murray</td>
</tr>
<tr>
<td></td>
<td>The selected ones (Oral Abstracts) (Theme F)</td>
</tr>
<tr>
<td>14:45 - 15:30</td>
<td>Plenary Lecture: Effects of cannabis in adolescence and depression risk in young adulthood: From animals to humans studies - Gabriella Gobbi, McGill University, Canada</td>
</tr>
<tr>
<td>15:45 - 16:15</td>
<td>Closing Ceremony</td>
</tr>
</tbody>
</table>

---

**Legend**

- Plenary Lecture
- Symposium
- Debate
- Regional Symposium
- Pre-Congress Workshop
- Clinical Focus and Frontiers
- The Selected One
- Session in Chinese
- Other
08.45 - 09.30 | Plenary Hall

PLENARY LECTURE

From genes to clinical phenotype in ADHD across the lifespan
Barbara Franke, Radboud University, The Netherlands

10.00 – 11.30 | Room 201 A+B+C

SYMPOSIUM 1

Chair: Anthony Grace, USA

Gene-environment interaction in schizophrenia: Genetic load modulates the deleterious impact of stressors to lead to the emergence of psychosis

1. Cannabis-associated psychosis; mechanisms and implications
Robin Murray, UK

2. The neuroimmune hypothesis of schizophrenia and cannabis use relevance in youth - novel studies with TSPO PET
Romina Mizrahi, Canada

3. Inability to regulate stress prepubertally as a risk factor for schizophrenia: disregulation of prefrontal-amygdala-hippocampal circuitry
Anthony Grace, USA

4. A convergent circuit for genetic and environmental risk for schizophrenia
Andreas Meyer-Lindenberg, Germany

SYMPOSIUM 2

Chair: Siegfried Kasper, Austria

Treatment Resistant Depression (TRD)

1. Characterization of treatment resistant depression in Europe
Siegfried Kasper, Austria

2. Genetic findings in TRD
Chiara Fabbri, Italy

3. Glutamateric approach in TRD
Carlos Zarate, USA

4. Deep brain stimulation in TRD
Thomas Schläpfer, Germany

SYMPOSIUM 3

Chair: Hiroyuki Uchida, Japan

Novel brain imaging strategies to assess pathophysiology and treatment effects in neuropsychiatric disorders

1. A novel PET tracer for AMPA receptors characterizes neuropsychiatric disorders in human
Takuya Takahashi, Japan

2. First PET imaging of AMPA receptors in schizophrenia and depression
Hiroyuki Uchida, Japan

3. Antipsychotic effect on glutamate and dopamine system in first-episode psychosis
Euitae Kim, Republic of Korea

4. How childhood trauma induces changes in dopaminergic function to give rise to psychopathology
Michael Bloomfield, UK
**Preliminary Programme**

**Friday, 26 June 2020**

11.30 – 13.00

**Lunch**

**Satellite Symposia**

**Plenary Educational Workshop**

Meet with...

*John Krystal: Psychosis*
*Katharina Domschke: Anxiety*

*Attendance limited. Pre-registration required; preference given to CINP members*

13.00 – 14.30  |  Plenary Hall

**SYMPOSIUM 4**

*Chair: Ke Xu, USA*

**Substance abuse and psychosis: New insights on old problems**

1. The complex relationships between cannabinoids and psychosis
   *Deepak Cryil D’Souza, USA*

2. Psychotic and cognitive profiles among chronic ketamine abusers with KAP
   *Ni Fan, China*

3. Genetic and epigenetic vulnerability of health cannabis users and the dynamic arena of medical cannabis
   *Celia Morgan, UK*

4. Shared vulnerability and neural pathways between ketamine-associated psychosis and schizophrenia
   *Ke Xu, USA*

13.00 – 14.30  |  Room 201 A+B+C

**SYMPOSIUM 5**

*Chair: Steven Potkin, USA*

**Partial dopamine agonists: Wide spectrum medications for psychiatric disorders**

1. *in vitro pharmacological profiles of aripiprazole, brexpiprazole, and cariprazine*
   *Pierre Blier, Canada*

2. Clinical effects of aripiprazole in schizophrenia
   *Steven Potkin, USA*

3. The role of brexpiprazole in the treatment of inadequate response in major depressive disorder
   *Diane McIntosh, Canada*

4. Long-term use of cariprazine in bipolar disorder
   *Terence Ketter, USA*

13.00 – 14.30  |  Room 201 D+E+F

**SYMPOSIUM 6**

*Chair: Paul Appelbaum, USA*

**Ethical Challenges of Genomic Research in Neuropsychiatric Disorders**

1. *Returning Results in Psychiatric Genomic Research: Ethical Conundra*
   *Gabriel Lazaro-Munoz, USA*

2. Informed Consent to Psychiatric Genomic Research
   *Paul Appelbaum, USA*

3. NeuroGene, Neuropsychiatric Gen-Ethics, and the Dilemma of Facial Phenotyping
   *Ilina Singh, UK*

4. Developing Responsible Governance for Genomic Research in Neuroscience
   *Adrian Thorogood, Canada*

13.00 - 14:30  |  Room 102

**CLINICAL FOCUS AND FRONTIERS**

**OCD**

1. Diagnosis
   *Joseph Zohar, Israel*

2. Therapeutics
   *Naomi Fineberg, UK*
**SYMPOSIUM 7**
*Chair: Hsien-Yuan Lane, Taiwan*

The Interplay of stress cascade and NMDAR dysfunction in the pathogenesis of mental disorders: Identifying novel antioxidants and NMDAR modulators for treatment and diagnosis

1. Prevention of neurodevelopmental disorders in offspring after maternal immune activation
   **Kenji Hashimoto**, Japan

2. Oxidative stress and inflammation in schizophrenia pathophysiology: add-on trial with N-acetyl-cysteine (NAC) in early psychosis patients, towards biomarker guided treatment
   **Kim Q. Do**, Switzerland

3. Identifying novel NMDAR modulators and antioxidants for the treatment of mental disorders
   **Hsien-Yuan Lane**, Taiwan

4. NMDAR- and antioxidants-related potential biomarkers for mental disorders
   **Chieh-Hsin Lin**, Taiwan

**SYMPOSIUM 8**
*Chair: William E. Bunney, USA*

Altered Circadian Rhythms in Psychiatric Mood Disorders: New Treatment Strategies

   **Colleen A. McClung**, USA

2. Abnormal Core Clock Genes in MDD: Potential Resetting with Rapid-Acting Antidepressants
   **William E. Bunney**, USA

3. Adjustment of Central and Peripheral Circadian Clocks in Humans
   **Diane B. Boivin**, Canada

4. Light Signaling Alterations and Light Use in Depression
   **Pierre A. Geoffroy**, France

**SYMPOSIUM 9**
*Chair: Kazutaka Ikeda, Japan*

Opioid Pharmacology Updates: Toward precision pharmacotherapy

1. Transcriptional regulation of opioid withdrawal and microglia reactivity in humans and rodents
   **Tuan Trang**, Canada

2. Involvement of adhesion molecules in heroin- dependent patients in methadone maintenance therapy
   **Yu-Li Liu**, Taiwan

3. Opioid receptor gene variation that moderates opioid pharmacotherapy
   **Henry Kranzler**, USA

4. Genetic mechanisms underlying individual differences in opioid sensitivity revealed by genome-wide association studies
   **Kazutaka Ikeda**, Japan

**DEBATE**
*Cannabinoids*

**Gabriella Gobbi** vs. **David Nutt**

**CLINICAL FOCUS AND FRONTIERS**

**ADHD**

**Barbara Franke**, The Netherlands

**Judith Rapoport**, USA

16.15 – 16.45

Networking Break
16.45 – 17.30 | Plenary Hall

PLENARY LECTURE

What is life: Implications for brain health

Josef Penninger, Life Sciences Institute, UBC, Canada

18.00 – 19.30

Top 10 Posters - Guided Session
08.45 - 09.30 | Plenary Hall

**PLENARY LECTURE**

Big data analyses for neuropsychopharmacology

Tung-Ping Su, Cheng-Hsin General Hospital, Taiwan

09.30 - 10:00

**Networking Break**

10:00 – 11.30 | Plenary Hall

**SYMPOSIUM 10**

Chair: Karen Ersche, UK

**Risk and Resilience in Addiction**

1. Network failure predisposes individuals for addiction

Karen Ersche, UK

2. When drug meets vulnerability: how drugs of abuse take advantage of pre-existing brain abnormality

Karine Guillem, France

3. Preclinical models of adolescent drug exposure and their consequences for later life

Shannon Gourley, USA

4. The long-term consequences of adolescent drug use

Francesca Filbey, USA

10:00 – 11.30 | Room 201 A+B+C

**SYMPOSIUM 11**

Chair: Rainer Rupprecht, Germany

**Novel mechanisms of action of antidepressant treatment**

1. Role of lipid rafts and G-protein signalling for antidepressant drug treatment

Mark Rasenick, USA

2. Role of glial cells and TSPO for antidepressant and anxiolytic drug treatment

Rainer Rupprecht, Germany

3. Role of neuroplasticity for treatment of depression with antidepressants and psychotherapy

Eero Castren, Finland

4. Role of endocannabinoid signaling for the antidepressant activity of omega-3 fatty acids

Kuan Pin Su, Taiwan

10.00 – 11.30 | Room 201 D+E+F

**SYMPOSIUM 12**

Chair: Maurizio Popoli, Italy

**Mechanisms of stress in pathophysiology of brain illness**

1. Roles and mechanisms of neuroinflammation in chronic stress-induced behavioral changes

Tomoyuki Furuyashiki, Japan

2. Microbiota-gut-brain (MGB) axis and mental disorder

Tallie Baram, USA

3. Dynamic dissection of the stress response: a matter of resilience or vulnerability

Maurizio Popoli, Italy

4. How life experiences leave traces in descendants. Epigenetic mechanisms in the germline

Isabelle Mansuy, Switzerland

11.30 – 13.00

**Lunch**

**Satellite Symposia**

Plenary Educational Workshop

Meet with...

Naomi Fineberg: OCD*

Pierre Blier: TRD*

*Attendance limited. Pre-registration required; preference given to CINP members
13.00 – 14.30  |  Plenary Hall

SYMPOSIUM 13
Chair: Gerhard Gründer, Germany

Molecular imaging in drug development: Is there any progress?
1. Molecular Imaging in Psychotropic Drug Development: Principles, Pitfalls and Promises
   Gerhard Gründer, Germany
2. Imaging Methods to Optimize CNS Drug Development
   Eugenii A. (Ilan) Rabiner, UK
3. Molecular Imaging in the Development of Novel Disease-Specific Therapeutics for Dementia
   Victor Villemagne, Australia
4. Neuroreceptor Imaging of Target Engagement of New Antipsychotics in Schizophrenia
   Dean F. Wong, USA

13.00 – 14.30  |  Room 201 A+B+C

SYMPOSIUM 14
Chair: Sam Chamberlain, UK

Impulsive-compulsive disorders: where neurobiology meets evidence-based treatment
1. Introducing impulsivity-compulsivity: from symptoms to prediction of latent trans-diagnostic phenotypes
   Sam Chamberlain, UK
2. Neurobiology of impulsive and compulsive disorders: the ENIGMA variations
   Dan Stein, South Africa
3. Problematic Use of the Internet (PUI): a new mental disorder? Diagnostic and cognitive considerations
   Naomi Fineberg, UK
4. New treatments for impulse control disorders and OCD identified using neurobiological models
   Jon Grant, USA

13.00 – 14.30  |  Room 201 D+E+F

SYMPOSIUM 15
Chair: Katharina Domschke, Germany and Arturas Petronis, Canada

Epigenetics in Aging, Anxiety- and Stress-Related Disorders – Progress, Perspectives and Pitfalls
1. Circadian oscillations in epigenetics and their relevance to aging and mental disorders
   Arturas Petronis, Canada
2. Epigenetics – the role of risk and resilience in PTSD
   Divya Mehta, Australia
3. Patho- and therapy-epigenetics of anxiety and affective disorders
   Katharina Domschke, Germany
4. Histone acetylation as potential target for the therapy of pathological fear and anxiety
   Nicolas Singewald, Austria

13:00 - 14:30  |  Room 102

CLINICAL FOCUS AND FRONTIERS

Depression
1. Mechanisms
   Elias Eriksson, Sweden
2. Evidence
   Carlos Zarate, USA

14.45 – 16.15  |  Plenary Hall

SYMPOSIUM 16
Chair: Brian Dean, Australia

The Importance of the Muscarinic M1 Receptor in CNS Function and as a Drug Target for Cognitive Deficits and Sleep in Schizophrenia
1. Evidence suggesting the muscarinic M1 receptor has a role in the aetiology and treatment of schizophrenia
   Brian Dean, Australia
2. The role of CHRM1 signalling in cognitive and behavioural symptoms of psychosis
Geor Bakker, The Netherlands

3. Systems Biology of Mammalian Sleep/Wake Cycles: The roles of muscarinic acetylcholine receptor in NREM and REM sleep
Hiroki Ueda, Japan

4. Safety and Pharmacodynamic Effects of M1 agonists in Humans
Pradeep Nathan, UK

14.45 – 16.15  |  Room 201 A+B+C

SYMPOSIUM 17
Chair: Pierre Blier, Canada

Rapid onset and sustained action of ketamine in depressive episodes: from the laboratory to the community
1. Impact of ketamine on the intracellular signaling beyond the N-methyl-D-aspartate receptors
Lisa Monteggia, USA

2. Neural networks involved in the action of ketamine
Carlos Zarate, USA

3. Three-phase study of intravenous ketamine
Jennifer Phillips, Canada

4. Ketamine infusions
Steve Levine, USA

14:45 - 16:15  |  Room 101 C+D

DEBATE
Pharmacogenetics
Alessandro Serretti vs. Henk-Jan Guchelaar

14:45 - 16:15  |  Room 102

CLINICAL FOCUS AND FRONTIERS
Difficult to treat psychosis
1. Therapeutic approaches
Steven Potkin, USA

2. Pathophysiology and mechanisms of action
Anthony Grace, USA

16.15 – 16.45
Networking Break

16.45 – 17.30  |  Plenary Hall

PLENARY LECTURE
Brain mechanisms of insomnia: fMRI and GWAS perspectives on causes and consequences
Eus Van Someren, Vrije Universiteit Amsterdam, The Netherlands
08.45 - 09.30 | Plenary Hall

PLENARY LECTURE

Transgenerational epigenetics: A key to understand neurodevelopmental diseases
Noriko Osumi, Tohoku University, Japan

09.30 - 10:00

Networking Break

10:00 – 11.30 | Plenary Hall

SYMPOSIUM 19

Chair: Mark Weiser, Israel

Estrogen and psychiatric illnesses

1. Aromatase in the brain and human personality
Kayo Takahashi, Japan

2. Circuit and Cellular Substrates of the Differential Behavioral Response to Ovarian Steroids in Women with Reproductive Endocrine-related Mood Disorders
Peter Schmidt, USA

3. Prenatal steroid hormones and autistic traits in expectant mothers and their children
Alexandros Tsompanidis, UK

4. Effect of adjunctive estradiol on schizophrenia among women of childbearing age: A randomized controlled trial
Mark Weiser, Israel

10:00 – 11.30 | Room 201 A+B+C

SYMPOSIUM 20

Chair: W. Brad Ruzicka, USA

Epigenomic pathophysiology of Bipolar Disorder: Human tissue investigations of mechanisms, biomarkers, and single-cell pathology

1. Genome-wide DNA methylomic differences between dorsolateral prefrontal and temporal pole cortices of bipolar disorder
Marin Veldic, USA

2. DNA repair gene promoter methylation in postmortem gray matter of patients with bipolar disorder
Aysegul Ozerdem, Turkey

3. Single-cell transcriptomics reveals cell population specific pathologies in bipolar disorder
W. Brad Ruzicka, USA

4. Membrane protein clustering in peripheral lymphocytes as a putative biomarker of mood and psychotic disorders
Hector Caruncho, Canada

10:00 – 11.30 | Room 201 D+E+F

SYMPOSIUM 21

Chair: David Nutt, UK and Rupert Lanzenberger, Austria

Stronger together? Using PET and MRI in neuropsychopharmacology

1. 5-HT2A receptor PET, serotonin release and amygdala fMRI responses in depression
David Nutt, UK

2. 5-HT reuptake site and 5-HT1A receptor imaging and emotions
Rupert Lanzenberger, Austria

3. Mu-opioid receptor availability and functional connectivity during reward processing in gambling disorder
Chen-Chia Lan, Taiwan

4. Dopamine D2 receptors: simultaneous PET measures and fMRI signals
Bruce Rosen, USA
Preliminary Programme

Sunday, 28 June 2020

10:00 - 11:30  |  Room 102

CLINICAL FOCUS AND FRONTIERS

Insomnia

Eus van Someren, The Netherlands
Diane Boivin, Canada

11.30 – 13.00  
Lunch

Satellite Symposia

Plenary Educational Workshop

Meet with...

Gabriella Gobbi: Cannabis*
Elias Eriksson: Antidepressants*
*Attendance limited. Pre-registration required; preference given to CINP members

13.00 – 14.30  |  Plenary Hall

SYMPOSIUM 22

Chair: Eileen Lueders, New Zealand

Transgender hormone therapy: effects on brain structure and function

1. Hormonal treatment effects on the brain: findings from the Enigma transgender persons working group
Sven C. Müller, Belgium

2. Sex matters – a multivariate pattern analysis of sex and gender
Pia Baldinger-Melich, Austria

3. Effects of sex hormones on serotonergic neurotransmission
Georg S. Kranz, Hong Kong

4. A new theory about the neurobiology of gender dysphoria
Sarah M. Burke, The Netherlands

13.00 – 14.30  |  Room 201 A+B+C

SYMPOSIUM 23

Chair: Gustavo Turecki, Canada

Mechanisms of stress response at the single cell resolution

1. The neuroendocrine stress response at a single cell resolution
Alon Chen, Israel

2. Single-cell transcriptomic changes in the hippocampus of non-human primates as a function of stress and treatment response
Michael Meaney, Singapore

3. Using brain organoids to model stress at the single cell resolution
Elisabeth Binder, Germany

4. LCM-Seq: single cell-type transcriptomic profiling of the prefrontal cortex as a function of childhood abuse
Gustavo Turecki, Canada

13.00 – 14.30  |  Room 201 D+E+F

SYMPOSIUM 24

Chair: Kenji Hashimoto, Japan

Novel Molecular and Cellular Mechanisms of Rapid-acting Antidepressant Ketamine and Its Enantiomers

1. Molecular mechanisms underlying rapid-acting and long-lasting antidepressant effects of ketamine
Kenji Hashimoto, Japan

2. Role of immune system in rapid-acting and long-lasting antidepressant effects of ketamine
Kai Zhang, China

3. Rapamycin, an immunosuppressant and mTORC1 inhibitor, triples the antidepressant response rate of ketamine at 2 weeks following treatment: A double-blind, placebo-controlled, cross-over, randomized clinical trial.
Chadi G. Abdallah, USA

4. New clinical developments for treatment-resistant depression and suicidality
Sanjay J. Mathew, USA

2020 CINP World Congress
13:00 - 14:30  |  Room 101 A+B

DEBATE

Is long-term treatment with antipsychotics justified?

Konstantinos Fountoulakis vs. Robin Murray

14.45 – 15.30  |  Plenary Hall

PLENARY LECTURE

Effects of cannabis in adolescence and depression risk in young adulthood: From animals to human studies

Gabriella Gobbi, McGill University, Canada

15.45 – 16.15  |  Plenary Hall

Closing Ceremony
From genes to clinical phenotype in ADHD across the lifespan

Barbara Franke, PhD is professor of Molecular Psychiatry at Radboud University in Nijmegen, The Netherlands, where she is based at the Human Genetics and Psychiatry departments of the Radboud UMC. Her research is focused on understanding the genetic contribution to neurodevelopmental psychiatric disorders, especially ADHD and its comorbidities.

What is life: Implications for brain health

Josef Penninger, MD was formerly a lead researcher at the Amgen Research Institute in Toronto. Since 2002 he was the founding and scientific director of the newly established Institute of Molecular Biotechnology in Austria. 2018 he accepted the appointment as Director of the Life Sciences Institute at the University of British Columbia in Canada.
Plenary Speakers

Saturday 27 June 2020
08:45 – 09:30

Big data analyses for neuropsychopharmacology

Tung-Ping Su,
Cheng-Hsin General Hospital, Taiwan

Professor Tung-Ping Su is the chair of the Department of Psychiatry, Cheng-Hsin General Hospital and Professor Emeritus of National Yang-Ming University, Taipei, Taiwan. Dr. Su was the previous president of AsCNP. His interests are studying mood disorders and brain imaging. Dr. Su is one of the pioneers conducting clinical trials on ketamine and depression in the Asian populations and is the recipient of the “Academic Achievement Award” from the Taiwanese Society of Psychiatry.

Saturday 27 June 2020
16:45 – 17:30

Brain mechanisms of insomnia: fMRI and GWAS perspectives on causes and consequences

Eus Van Someren,
Vrije Universiteit Amsterdam, The Netherlands

Prof. Eus Van Someren was trained in physics, psychophysiology and neuropsychology and received a cum laude PhD in neurobiology from the faculty of medicine. He leads a team at the Netherlands Institute for Neuroscience, aiming to unravel brain mechanisms of chronic insomnia. He received prestigious grants including VIDI, VICI and ERC-AdG, and founded the Sleep Registry (sleepregistry.org) for rich phenotyping of over 10,000 volunteers. He (co)-authored on more than 250 peer-reviewed publications in scientific journals including NJEM, Jama, Nature Genetics, Nature Neuroscience, Lancet Psychiatry, Archives of General Psychiatry, Psychological Bulletin, Brain and PNAS and is widely cited (H-index 53). His informal infectious enthusiasm for a neuroscience of insomnia make him a frequently invited speaker, e.g. at TED-X.
**Plenary Speakers**

**Sunday 28 June 2020**
08:45 – 09:30

Transgenerational epigenetics: A key to understand neurodevelopmental diseases

Noriko Osumi, Tohoku University, Japan

Prof. Osumi has graduated Tokyo Medical and Dental University, been given PhD thesis from the same university, and now is a professor of Tohoku University School of Medicine since 1998. She is appointed in various governmental committees such as ethical issues, grant system development, and career paths for young scientists, and also chosen as a youngest member of Japanese Council Japan since 2005. Her research interest covers broad areas such as pre- and postnatal development of the brain and craniofacial region, and behavior of animals as models of psychiatric diseases. More specifically, she is recently eager to understand regulatory mechanisms of neurogenesis and maintenance of neural stem cells at cellular and molecular levels both in embryonic and postnatal stages. Manipulating embryos and imaging brain cells are expertise of her lab.

**Sunday 28 June 2020**
16:45 – 17:30

Effects of cannabis in adolescence and depression risk in young adulthood: From animals to human studies

Gabriella Gobbi, McGill University, Canada

Dr. Gabriella Gobbi is a Professor in the Department of Psychiatry, McGill University. She leads a laboratory of basic science (Neurobiological Psychiatry Unit) and works as a Staff Psychiatrist at the Mood Disorder Clinic of the McGill University Health Center. Her research approach spans from bench to bedside, bridging the gaps between fundamental and clinical research. Dr. Gobbi received her MD (1991) and her specialty in Psychiatry and Psychotherapy (1995) from the Catholic University of Rome (Italy). She also earned a PhD in Neuroscience at the University of Cagliari, Italy) and finalized a post-doc at McGill University (Montreal, Canada) in 1998. Dr Gobbi’s lab is interested in understanding the pathophysiology of major depression and sleep related disorders and in the discovery of new treatments and cures for them. In particular, her laboratory is studying the short- and long-term effects of cannabis use in mood and anxiety, and the potential beneficial effects of the drugs acting on the endocannabinoid system (endogenous cannabis) in the cure of mental diseases. Her lab is also studying the effect of melatonin in mood, anxiety and sleep regulation in an effort to understand how novel selective ligands for melatonin receptors (called MT1 and MT2 receptors) can be used to treat seasonal depression, major depression, sleep disorders, as well as pain.
CINP Head Office
Nußdorfer Straße 20/24
1090 Vienna
Austria
Phone: +43 1 3532024
Fax: +1 604 681 1049
info@cinp.org
www.cinp.org

For further information on CINP and to keep up to date with all CINP activities please visit www.cinp.org